Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort
| Status: | Archived |
|---|---|
| Conditions: | Alzheimer Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2010 |
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Doses of E2609 in Healthy Subjects and an Elderly Cohort
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of E2609 when administered as single doses to healthy adult volunteers and
healthy elderly subjects.
The study will consist of 2 parts: (1) a single dose in healthy adult volunteers, at doses
up to 100 mg or the maximum dose that can be tolerated, (2) a single dose of 25 mg or lower
in healthy elderly volunteers.
We found this trial at
1
site
Click here to add this to my saved trials
